| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| Other Sizes |
| Targets |
Multiple targets including: platelet aggregation pathway (arachidonic acid-induced), tumor cell viability, and mycobacterial growth. The precise molecular target of Pangelin has not been fully elucidated, but its biological activities suggest interactions with pathways involved in cell proliferation, inflammation, and hemostasis.
|
|---|---|
| ln Vitro |
Pangelin demonstrates strong cytotoxic action against four different types of tumor cell lines, with IC50s ranging from 8.6 to 14.6 μg/mL[1].
In vitro, Pangelin exhibits potent cytotoxic activity against four tumor cell lines with IC50 values ranging from 8.6 to 14.6 µg/mL. It shows μM-level inhibition of arachidonic acid-induced platelet aggregation. The compound also demonstrates anti-mycobacterial activity, indicating potential as an antimicrobial agent. Its mechanism may involve modulation of inflammatory mediators and induction of oxidative stress in target cells. |
| ln Vivo |
In vivo activity data for Pangelin are limited in the available literature. Based on its in vitro anti-tumor and anti-platelet activities, further studies in animal models would be warranted to evaluate its potential therapeutic efficacy. The compound is primarily studied as a natural product for pharmacological characterization rather than as a clinical candidate at this stage.
|
| Enzyme Assay |
Platelet aggregation inhibition is assessed using platelet-rich plasma (PRP) isolated from human or animal blood. PRP is incubated with varying concentrations of Pangelin, and aggregation is induced by arachidonic acid. Aggregation is measured using a platelet aggregometer, and the IC50 is determined. Anti-mycobacterial activity is evaluated using broth microdilution assays against Mycobacterium tuberculosis strains to determine minimum inhibitory concentrations (MICs).
|
| Cell Assay |
Tumor cell lines (e.g., four different cancer cell lines) are cultured in appropriate medium and treated with Pangelin at varying concentrations for 48-72 hours. Cell viability is assessed using MTT, CCK-8, or SRB assays. The IC50 values (8.6-14.6 µg/mL) are calculated from dose-response curves. Further mechanistic studies may include apoptosis detection, cell cycle analysis, and assessment of inflammatory markers.
|
| Animal Protocol |
Specific in vivo protocols for Pangelin are not well-documented. Standard approaches for evaluating anti-tumor activity would involve xenograft mouse models, while anti-platelet activity could be assessed in thrombosis models. Oral or intraperitoneal administration would be used, with doses determined from preliminary pharmacokinetic and tolerability studies. Further research is needed to establish in vivo efficacy.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Pangelin are not extensively characterized in the available literature. The compound has molecular formula C16H14O5 and molecular weight 286.28. It is soluble in DMSO (40 mg/mL, 139.72 mM). Its oral bioavailability, half-life, and tissue distribution require further investigation. As a natural product, its pharmacokinetic properties may vary depending on the source and formulation.
|
| Toxicity/Toxicokinetics |
No comprehensive toxicity data are currently available for Pangelin. As a natural coumarin compound, its safety profile would need to be evaluated in standard toxicological studies. The compound is generally considered for research use only, and caution should be exercised regarding potential coumarin-related hepatotoxicity, which is a class effect of some coumarin derivatives.
|
| References | |
| Additional Infomation |
It has been reported that pangelin is found in Angelica japonica, Ducrosia anethifolia, and other organisms with available data. See also: Pabulenol (note moved to).
Pangelin is a naturally occurring coumarin found in Ducrosia anethifolia, Angelica dahurica, and other plant species. It exhibits anti-mycobacterial, anti-tumor, and anti-platelet aggregation activities. The compound is supplied as a white to off-white solid powder with purity ≥98% and CAS number 33783-80-1. It is for research use only and has not entered clinical trials or received FDA approval. |
| Molecular Formula |
C16H14O5
|
|---|---|
| Molecular Weight |
286.28
|
| Exact Mass |
286.084
|
| CAS # |
33783-80-1
|
| PubChem CID |
44144315
|
| Appearance |
White to off-white solid powder
|
| Melting Point |
123 - 125 °C
|
| LogP |
2.855
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
21
|
| Complexity |
458
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
CC(=C)[C@H](COC1=C2C=CC(=O)OC2=CC3=C1C=CO3)O
|
| InChi Key |
BVMOMQJYQYBMKL-LBPRGKRZSA-N
|
| InChi Code |
InChI=1S/C16H14O5/c1-9(2)12(17)8-20-16-10-3-4-15(18)21-14(10)7-13-11(16)5-6-19-13/h3-7,12,17H,1,8H2,2H3/t12-/m0/s1
|
| Chemical Name |
4-[(2R)-2-hydroxy-3-methylbut-3-enoxy]furo[3,2-g]chromen-7-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : 50 mg/mL (174.65 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (4.37 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 12.5 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.4931 mL | 17.4654 mL | 34.9308 mL | |
| 5 mM | 0.6986 mL | 3.4931 mL | 6.9862 mL | |
| 10 mM | 0.3493 mL | 1.7465 mL | 3.4931 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
